SCHEMBL6161279

SCHEMBL6161279

c1ccc2cc(-c3c[nH]nn3)ccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.50
ALDH1A1 P00352 3/20 0.50
CYP2C9 P11712 2/20 0.50
HPGD P15428 2/20 0.50
CYP2C19 P33261 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.46
AR P10275 2/20 0.46
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
MAPT P10636 1/20 0.46
NFKB1 P19838 1/20 0.46
RAB9A P51151 1/20 0.46
GFER P55789 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
CYP1A1 P04798 1/20 0.46
CYP1B1 Q16678 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29699377 0.82 CYP2A6 (0.39) CYP1A2ALDH1A1CYP2C9HPGDCYP2C19
SCHEMBL14260684 0.80 TDO2 (0.50) CYP11B1CYP11B2
SCHEMBL28728221 0.78 CYP1A2 (0.49) CYP1A2ALDH1A1CYP2C19NPC1RAB9A
SCHEMBL5612751 0.78 NPSR1 (0.35) CYP1A2ALDH1A1CYP2C9HPGDCYP2C19
SCHEMBL1646236 0.78 GP6 (0.37) CYP1A2ALDH1A1CYP2C9CYP2C19RAB9A
SCHEMBL13078874 0.77 METAP2 (0.32) SMN1; SMN2NPC1RAB9A
SCHEMBL12989702 0.76 AKT1 (0.48) CYP1A2ALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL19723355 0.76 PDGFRB (0.50) CYP1A2ALDH1A1NPC1MAPTRAB9A
SCHEMBL9868 0.76 AKT1 (0.46) CYP1A2ALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL22276765 0.74 NPC1 (0.49) ALDH1A1CYP11B1CYP11B2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143578-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2005-06-30 US claimed
EP-1434772-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2005-05-04 EP claimed
US-20040192914-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2004-09-30 US claimed
EP-1434772-A1 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2004-07-07 EP claimed
US-20030220371-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2003-11-27 US claimed
EP-1274424-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2003-09-17 EP claimed
WO-2003031434-A1 COMPOUNDS AND METHODS SMITH KLINE BEECHAM CORPORATION (US) 2003-04-17 WO claimed
EP-1274424-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-15 EP claimed
WO-2001078723-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2001-10-25 WO claimed
CN-104185669-B Cooling liquid composition CCI株式会社 2017-02-22 CN disclosed
CN-104185669-A Cooling liquid composition CCI CORP 2014-12-03 CN disclosed
US-20050143578-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2005-06-30 US disclosed
EP-1434772-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2005-05-04 EP disclosed
US-20050004116-A1 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents SMITHKLINE BEECHAM CORPORATION 2005-01-06 US disclosed
US-20030220371-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2003-11-27 US disclosed
EP-1274424-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2003-09-17 EP disclosed
WO-2003031434-A1 COMPOUNDS AND METHODS SMITH KLINE BEECHAM CORPORATION (US) 2003-04-17 WO disclosed
EP-1274424-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-15 EP disclosed
WO-2001078723-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2001-10-25 WO disclosed
US-4060570-A BUTYL RUBBER OR POLYBUTENE ADHESIVE, OIL ABSORBENT FILLER THIOKOL CORPORATION (US) 1977-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192914-A1 Compounds and methods METAP2, METAP1, DNPEP CYP1A2 1882/4885ALDH1A1 677/4885CYP2C9 2025/4885
US-20050004116-A1 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents METAP1, METAP2, DNPEP CYP1A2 3328/4885ALDH1A1 1107/4885CYP2C9 3916/4885
US-20030220371-A1 Compounds and methods METAP2, METAP1, DNPEP CYP1A2 3077/4885ALDH1A1 1579/4885CYP2C9 4109/4885
US-20050143578-A1 Compounds and methods METAP2, METAP1, DNPEP CYP1A2 1632/4885ALDH1A1 977/4885CYP2C9 2092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.